Literature DB >> 32986343

P53 Expression in benign Breast Disease Development: A Systematic Review.

Rafaela Soares Senra da Costa1, Ilce Ferreira Da Silva1.   

Abstract

BACKGROUND: Benign breast disease (BBD) is one of main breast cancer risk factors. Dysfunctions on p53 protein, which has a genome protective role, have been related to breast cancer developments. However, its role on BBD development is still unclear.
METHODS: A systematic review of literature was proceeded according to PRISMA-P guidelines. PubMed, BVS, MEDLINE and Scholar Google were used as databases, complemented by a manual search in articles references.  Articles searches were conducted from May to July 2019 and publications in English, Spanish and Portuguese were selected. P53 expression was set as outcome among women with BBD and were included only articles with good quality according STROBE tools. Data concerning p53 expression frequencies were independently extracted by two review authors, and eligible articles were synthesized.
RESULTS: From 12 studies selected for this review, the majority analyzed p53 expression in non-proliferative lesions and general p53 expressions ranged from 0 to 100%. P53 expression was more frequently observed in cases series studies (91.7%) and in studies conducted in Occidental Europe (41.7%). P53 expression was more frequent among tissues with fibrocystic disease (22.5%) and fibroadenoma (22.5%).
CONCLUSION: When compared with all breast tissues types, benign breast disease corresponds to 34.39% of p53 expression. Second outcomes were not evaluated because the heterogeneity observed in selected studies. In addition, more studies considering ethnicity and benign breast disease classification should also be considered for further analysis.

Entities:  

Keywords:  Breast diseases; Epidemiology; Genetic polymorphism; public health

Mesh:

Substances:

Year:  2020        PMID: 32986343      PMCID: PMC7779431          DOI: 10.31557/APJCP.2020.21.9.2485

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  40 in total

1.  Conducting a meta-analysis: basics and good practices.

Authors:  Mike W-L Cheung; Roger C M Ho; Yonghao Lim; Anselm Mak
Journal:  Int J Rheum Dis       Date:  2012-02-22       Impact factor: 2.454

2.  DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies.

Authors:  G Casey; M E Lopez; J C Ramos; S J Plummer; M J Arboleda; M Shaughnessy; B Karlan; D J Slamon
Journal:  Oncogene       Date:  1996-11-07       Impact factor: 9.867

Review 3.  The p53 network.

Authors:  M L Agarwal; W R Taylor; M V Chernov; O B Chernova; G R Stark
Journal:  J Biol Chem       Date:  1998-01-02       Impact factor: 5.157

Review 4.  p53, the cellular gatekeeper for growth and division.

Authors:  A J Levine
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

5.  Atypical hyperplastic lesions of the female breast. A long-term follow-up study.

Authors:  D L Page; W D Dupont; L W Rogers; M S Rados
Journal:  Cancer       Date:  1985-06-01       Impact factor: 6.860

Review 6.  Breast cancer risk associated with benign breast disease: systematic review and meta-analysis.

Authors:  Sara W Dyrstad; Yan Yan; Amy M Fowler; Graham A Colditz
Journal:  Breast Cancer Res Treat       Date:  2015-01-31       Impact factor: 4.872

7.  Expression of c-myc, erbB-2, p53 and nm23-H1 gene product in benign and malignant breast lesions: coexpression and correlation with clinicopathologic parameters.

Authors:  Maja Sirotkovic-Skerlev; Simun Krizanac; Sanja Kapitanovic; Koraljka Husnjak; Josip Unusic; Kresimir Pavelic
Journal:  Exp Mol Pathol       Date:  2005-04-07       Impact factor: 3.362

8.  p53 accumulation in benign breast biopsy specimens.

Authors:  M Younes; R M Lebovitz; K E Bommer; P T Cagle; D Morton; S Khan; R Laucirica
Journal:  Hum Pathol       Date:  1995-02       Impact factor: 3.466

Review 9.  Anatomic indicators (histologic and cytologic) of increased breast cancer risk.

Authors:  D L Page; W D Dupont
Journal:  Breast Cancer Res Treat       Date:  1993-11       Impact factor: 4.872

10.  The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.

Authors:  Julian P T Higgins; Douglas G Altman; Peter C Gøtzsche; Peter Jüni; David Moher; Andrew D Oxman; Jelena Savovic; Kenneth F Schulz; Laura Weeks; Jonathan A C Sterne
Journal:  BMJ       Date:  2011-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.